O-GlcNAc transferase as an oncogenic regulator in hematologic malignancies: Mechanisms, disease contexts, and therapeutic perspectives
Identifying which blood cancer patients have a specific genetic marker could help doctors choose targeted therapies that block the protein driving their disease.
OGT exhibits highest expression in hematologic malignancies among all cancer lineages; four mechanistic axes defined—PD-L1-mediated immune evasion, phosphoproteome crosstalk, MYC/p53/STAT5 proteostatic stabilization, and EZH2/TET epigenetic reprogramming—with ASXL1 mutation status as the leading stratification biomarker for OGT-targeting therapy. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- systematic_review
- Category
- Other
- Maturity
- Validated
- Journal
- Biomed Pharmacother
Why it surfaced
Comprehensive mechanistic framework unifying OGT across major hematologic malignancies with clear clinical translation pathway; disease-highest OGT expression level identifies a unique oncobiological vulnerability; establishes stratification biomarkers (ASXL1, p53) enabling precision application.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.